Distinct neuroinflammatory profile in post-mortem human Huntington's disease

NeuroReport

Volumn 20, Issue 12, 2009, Pages 1098-1103

  Silvestroni, Aurelio ^a   Faull, Richard L M ^c   Strand, Andrew D ^b   Möllera, Thomas ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CCL2; Huntington's disease; IL 10; IL 6; IL 8; Microglia; MMP9; Neuroinflammation

Indexed keywords

GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; AUTOPSY; BRAIN CORTEX; CEREBELLUM; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MEDIATOR; NERVE CELL; NEUROINFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; CEREBELLUM; CEREBRAL CORTEX; CHEMOKINE CCL2; CORPUS STRIATUM; FEMALE; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68249112361     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32832e34ee     Document Type: Article

References (25)

1. Walker FO. Huntington's disease. Semin Neurol 2007; 27:143-150
2. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev 2005; 6:919-930. (Pubitemid 41753086)
3. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57:369-384.
4. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29:357-365.
5. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999; 159:362-376. (Pubitemid 29485223)
6. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60:161-172. (Pubitemid 32172419)
7. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6:797-801. (Pubitemid 30469429)
8. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999; 399:263-267. (Pubitemid 29246456)
9. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66:1638-1643. (Pubitemid 43964614)
10. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008; 205:1869-1877.
11. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006; 15:965-977. (Pubitemid 43338237)
12. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007; 16:1845-1861. (Pubitemid 47244533)
13. Weis S, Llenos IC, Dulay JR, Elashoff M, Martinez-Murillo F, Miller CL. Quality control for microarray analysis of human brain samples: the impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods 2007; 165:198-209. (Pubitemid 47212459)
14. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
15. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002; 35:419-432. (Pubitemid 34879943)
16. Hanisch UK. Microglia as a source and target of cytokines. Glia 2002; 40:140-155.
17. Jinno S, Fleischer F, Eckel S, Schmidt V, Kosaka T. Spatial arrangement of microglia in the mouse hippocampus: a stereological study in comparison with astrocytes. Glia 2007; 55:1334-1347. (Pubitemid 47328937)
18. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006; 24:1115-1122. (Pubitemid 44359723)
19. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22:101-109. (Pubitemid 43152029)
20. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007; 10:1355-1360.
21. Khabar KS. The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005; 25:1-10.
22. Ware CF. The TNF superfamily-2008. Cytokine Growth Factor Rev 2008; 19:183-186.
23. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007; 83:228-248.
24. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
25. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130:1759-1766 (Pubitemid 47343790)